<DOC>
	<DOCNO>NCT00962052</DOCNO>
	<brief_summary>The investigator ' long-term objective research develop innovative new test diagnostic laboratory use 1 ) detect methylated DNA target , 2 ) tumor specific antigen , 3 ) marker Bacillus Calmette-Guerin ( BCG ) treatment patient urine sample . The investigator plan detect methylated DNA target control target methylation-specific polymerase chain reaction ( msPCR ) DNA isolated urine sample bladder cancer positive negative patient determine sensitivity specificity detect bladder cancer . The investigator plan use patient serum tool detect tumor specific antigen express bladder cancer cell line . Once bladder tumor specific protein identify , investigator assess presence urine bladder cancer patient absence healthy patient enzyme-linked immunosorbent assay ( ELISA ) . The investigator plan use vitro model patient clinical sample elucidate role bladder epithelial cell mediate BCG immunotherapy identify biomarkers treatment effectiveness . Once biomarker identify , investigator assess presence urine bladder cancer absence healthy patient . Once investigator determine feasibility test , investigator perform extensive clinical study , compare test exist diagnostic method . This study provide foundation FDA approval , required test become widely accepted tool clinician use bladder cancer diagnosis . The investigator ' test improve early detection bladder cancer , thereby improve patient health decrease cancer death , key mission National Institutes Health .</brief_summary>
	<brief_title>Biomarker Discovery Application Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Over 18 year old No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>